Literature DB >> 23871248

Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens.

Paula A van Luijt1, Jacques Fracheboud, Eveline A M Heijnsdijk, Gerard J den Heeten, Harry J de Koning.   

Abstract

PURPOSE: To critically evaluate and confirm previous results regarding the diagnostic accuracy of digital mammography screening (DM), compared to screen-film mammography (SFM) in the whole Dutch screening programme, in the period of 2004-2010, during which a full transition from SFM to DM was made.
MATERIALS AND METHODS: 1.5 million DM and 4.6 million SFM were read in the Dutch national breast cancer screening programme in the period of 2004-2010. We evaluated recall rate, detection rate, positive predictive value and tumour-size distribution for younger and older women, for first time participants and women having a timely subsequent screen. We compared DM screens read by radiologists reading DM and SFM (DM-group) to SFM screens read by these radiologists (SFM-group) and to SFM screens read by radiologists reading only SFM (SFMonly-group).
RESULTS: Recall rate was 2.0% (95% confidence interval (C.I.): 2.0; 2.1) in the DM-group, compared to 1.6% (95% C.I.: 1.6; 1.6) in the SFM-group and 1.6% (95% C.I.: 1.5; 1.6) in the SFM only-group. The overall detection rates were 5.9/1000 screens (95% C.I.: 5.7; 6.0) in the DM-group, 5.1/1000 screens (95% C.I.: 5.0; 5.2) in the SFM-group and 5.0/1000 screens (95% C.I.: 5.0; 5.1) in the SFM only-group. Detection rate rose most markedly in younger women (age 49-54) from 4.0/1000 screens to 5.1/1000 screens (p-value<0.001). Positive predictive value (PPV) in DM rose from 18.4% (95% C.I.: 14.6; 23.1) in 2004 to 32.5% (95% C.I.: 31.7; 33.2) in 2010. Detection rate rose in SFM-group from 5.0/1000 screens (95% C.I.: 4.7; 5.3) in 2004 to 5.5/1000 screens (95% C.I.: 5.2; 5.7) in 2010. Detection rate in DM-group rose mostly due to ductal carcinoma in situ (DCIS) detection especially in younger women/first screens. The proportion of T1a tumours was significantly higher in DM-group; otherwise size distribution did not change significantly for invasive carcinoma. Recall rates were variable between different screening regions.
CONCLUSION: In accordance to previous, smaller, studies, we can confirm that DM has a higher detection rate compared to SFM, at the cost of a higher recall rate and lower PPV. More DCIS and a higher fraction of very small tumours were detected with DM, which has positive consequences for the stage shift as a result of mass screening.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Detection rate; Digital mammography; Mass screening; Positive predictive value; Recall rate

Mesh:

Year:  2013        PMID: 23871248     DOI: 10.1016/j.ejca.2013.06.020

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  22 in total

1.  Impact of the Introduction of Digital Mammography in an Organized Screening Program on the Recall and Detection Rate.

Authors:  Cinzia Campari; Paolo Giorgi Rossi; Carlo Alberto Mori; Sara Ravaioli; Andrea Nitrosi; Rita Vacondio; Pamela Mancuso; Antonella Cattani; Pierpaolo Pattacini
Journal:  J Digit Imaging       Date:  2016-04       Impact factor: 4.056

2.  Value of audits in breast cancer screening quality assurance programmes.

Authors:  Tanya D Geertse; Roland Holland; Janine M H Timmers; Ellen Paap; Ruud M Pijnappel; Mireille J M Broeders; Gerard J den Heeten
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

3.  Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study.

Authors:  Elena Leinert; Rolf Kreienberg; Achim Wöckel; Thorsten Kühn; Felix Flock; Ricardo Felberbaum; Wolfgang Janni; Kathy Taylor; Susanne Singer; Lukas Schwentner
Journal:  Arch Gynecol Obstet       Date:  2020-01-27       Impact factor: 2.344

4.  An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme.

Authors:  R G Blanks; R M Given-Wilson; S L Cohen; J Patnick; R J Alison; M G Wallis
Journal:  Eur Radiol       Date:  2019-02-04       Impact factor: 5.315

5.  Comprehensive quantitative malignant risk prediction of pure grouped amorphous calcifications: clinico-mammographic nomogram.

Authors:  Lijuan Shen; Tingting Jiang; Pengzhou Tang; Huijuan Ge; Chao You; Weijun Peng
Journal:  Quant Imaging Med Surg       Date:  2022-05

6.  Screening outcome in women repeatedly recalled for the same mammographic abnormality before, during and after the transition from screen-film to full-field digital screening mammography.

Authors:  Rob van Bommel; Adri C Voogd; Marieke W Louwman; Luc J Strobbe; Dick Venderink; Lucien E M Duijm
Journal:  Eur Radiol       Date:  2016-05-14       Impact factor: 5.315

Review 7.  Is the false-positive rate in mammography in North America too high?

Authors:  Michelle T Le; Carmel E Mothersill; Colin B Seymour; Fiona E McNeill
Journal:  Br J Radiol       Date:  2016-06-08       Impact factor: 3.039

8.  Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study.

Authors:  Elizabeth S Burnside; Daniel Vulkan; Roger G Blanks; Stephen W Duffy
Journal:  Radiology       Date:  2018-04-03       Impact factor: 11.105

9.  Differentiation of ductal carcinoma in-situ from benign micro-calcifications by dedicated breast computed tomography.

Authors:  Shadi Aminololama-Shakeri; Craig K Abbey; Peymon Gazi; Nicolas D Prionas; Anita Nosratieh; Chin-Shang Li; John M Boone; Karen K Lindfors
Journal:  Eur J Radiol       Date:  2015-10-01       Impact factor: 3.528

10.  Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.

Authors:  Lukas Schwentner; Reyn Van Ewijk; Thorsten Kühn; Felix Flock; Riccardo Felberbaum; Maria Blettner; Rolf Kreienberg; Wolfgang Janni; Achim Wöckel; Susanne Singer
Journal:  Support Care Cancer       Date:  2016-01-27       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.